


Dual CARs: What for?

- Despite progress in the field, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR T) experience relapse following a short-term response or do not respond to treatment.
- One of the major causes of **CAR T-cell resistance and relapse** is **antigen loss**, which results in the tumor cells losing the antigen targeted by the CAR T-cells. Unfortunately, this mechanism of tumor escape was also reported with other antigens targeted by CAR T-cells.
- One approach to overcome this loss is to develop a **dual or multi-targeting CAR strategy**. With a dual CAR, several antigens can be targeted together by the same CAR product so that if there is a loss of one antigen, there are still others that can work to kill the cancer cells.



NKG2D-based dual CAR

NKG2D ligands are broadly expressed on tumor cells across most solid tumors and hematological malignancies which makes them ideal targets for CAR T therapies. We are working to develop a dual CAR with NKG2D capabilities and an undisclosed target, which could be used to decrease risk of relapse or resistance often observed with traditional single-targeting CAR T approaches.